Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAT2A | P31153 | 1/20 | 0.34 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26912899 | 0.75 | HTR6 (0.39) | HTR6LMNAKMT2A | |
| SCHEMBL16916209 | 0.74 | CNR2 (0.38) | SRCGAAPTGDR2HTR6 | |
| SCHEMBL26913321 | 0.70 | SRC (0.36) | DCTPP1SRCPOLBHTR6KMT2A | |
| SCHEMBL26912986 | 0.70 | SIRT2 (0.37) | POLBKMT2AMAT2A | |
| SCHEMBL26912818 | 0.70 | SIRT2 (0.45) | MAT2A | |
| SCHEMBL15635129 | 0.69 | PTGDR2 (0.64) | PTGDR2HTR6 | |
| SCHEMBL26912373 | 0.67 | SRC (0.36) | DCTPP1SRCGAAACLYKMT2A | |
| SCHEMBL28802402 | 0.65 | KDM4E (0.44) | SRCHTR6ALDH3A1LMNA | |
| SCHEMBL27902312 | 0.65 | TDP1 (0.44) | DCTPP1SRCGAAPTGDR2POLB | |
| SCHEMBL20596677 | 0.64 | SRC (0.41) | SRCPTGDR2HTR6LMNAPTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023235809-A1 | CGAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2023-12-07 | — | — | WO | disclosed |
| US-20230391786-A1 | cGAS INHIBITORS | ELI LILLY AND COMPANY | 2023-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391786-A1 | cGAS INHIBITORS | CGAS, STING1, TBK1 | DCTPP1 994/4885SRC 1810/4885GAA 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.